Brief: Longeveron® Announces Completion Of Enrollment Of Pivotal Phase 2B Clinical Trial
24/06/2025 11:31
June 24 (Reuters) - Longeveron Inc LGVN.O: LONGEVERON® ANNOUNCES COMPLETION OF ENROLLMENT OF PIVOTAL PHASE 2B CLINICAL TRIAL EVALUATING LAROMESTROCEL AS A TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS) LONGEVERON INC - TOP-LINE TRIAL RESULTS EXPECTED IN Q3 2026 Source text: ID:nGNXbh8jKB Further company coverage: LGVN.O ((Reuters.Briefs@thomsonreuters.com;))